Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes pharmaceutical products. The Company develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. Vertex Pharmaceuticals serves the healthcare sector internationally.
Website: vrtx.com



Growth: Pretty weak revenue growth rate 9.3%, there is slowdown compared to average historical growth rates 16.9%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +18.8%

Profitability: LTM EBITDA margin is positive, +38.7%. On average the margin is decreasing unsteadily. Gross margin is high, +85.4%. In the last quarter the company beat the estimated EPS, +1.7%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.16 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 124.7% higher than minimum and 9.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.1x by EV / Sales multiple , the company can be 55.5% overvalued

Insiders: For the last 3 months insiders sold company shares on $24.6 mln (-0.023% of cap.)

Key Financials (Download financials)

Ticker: VRTX
Share price, USD:  (-0.8%)397.7
year average price 374.66  


year start price 339.37 2023-04-27

min close price 323.57 2023-05-31

max close price 440.11 2024-01-22

current price 397.70 2024-04-25
Common stocks: 256 900 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.5%
EV / LTM EBITDA: 24.0x
EV / EBITDA annualized: 22.6x
Last revenue growth (y/y):  9.3%
Last growth of EBITDA (y/y):  -4.2%
Historical revenue growth:  16.9%
Historical growth of EBITDA:  15.2%
EV / Sales: 9.3x
Margin (EBITDA LTM / Revenue): 38.7%
Fundamental value created in LTM:
Market Cap ($m): 102 169
Net Debt ($m): -10 494
EV (Enterprise Value): 91 675
Price to Book: 5.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-23Zacks Investment Research

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

2024-04-22The Motley Fool

If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today

2024-04-19Zacks Investment Research

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

2024-04-19The Motley Fool

Is Vertex Pharmaceuticals Stock a Millionaire Maker?

2024-04-16Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

2024-04-16Zacks Investment Research

Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?

2024-04-15Zacks Investment Research

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

2024-04-15The Motley Fool

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock

2024-04-12Proactive Investors

US biopharma first quarter earnings seen stable amid low expectations

2024-04-11The Motley Fool

Vertex Pharmaceuticals: Buy, Sell, or Hold?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2024-02-15 2023-11-07 2023-08-02 2023-05-02 2023-02-10 2022-10-28
acceptedDate 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 2 518M 2 484M 2 493M 2 375M 2 303M 2 334M
costOfRevenue 368M 319M 309M 267M 283M 289M
grossProfit 2 150M 2 165M 2 185M 2 108M 2 019M 2 045M
grossProfitRatio 0.854 0.872 0.876 0.888 0.877 0.876
researchAndDevelopmentExpenses 822M 810M 786M 743M 694M 645M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 369M 264M 263M 241M 267M 247M
otherExpenses -10M -16M 2M 1M -31M 0
operatingExpenses 1 191M 1 074M 1 048M 984M 962M 892M
costAndExpenses 1 559M 1 393M 1 357M 1 251M 1 245M 1 181M
interestIncome 180M 168M 145M 123M 86M 46M
interestExpense 11M 11M 11M 11M 12M 14M
depreciationAndAmortization 59M 205M 256M 469M 79M 100M
ebitda 1 018M 1 243M 1 283M 1 248M 1 113M 1 227M
ebitdaratio 0.404 0.501 0.514 0.526 0.483 0.526
operatingIncome 959M 1 038M 1 026M 779M 1 034M 1 127M
operatingIncomeRatio 0.381 0.418 0.412 0.328 0.449 0.483
totalOtherIncomeExpensesNet 189M -69M -108M 113M 43M 50M
incomeBeforeTax 1 148M 1 179M 1 162M 892M 1 077M 1 176M
incomeBeforeTaxRatio 0.456 0.475 0.466 0.375 0.468 0.504
incomeTaxExpense 179M 144M 246M 192M 258M 246M
netIncome 969M 1 035M 916M 700M 819M 931M
netIncomeRatio 0.385 0.417 0.367 0.295 0.356 0.399
eps 3.760 4.010 3.550 2.720 3.190 3.630
epsdiluted 3.710 3.970 3.520 2.690 3.150 3.590
weightedAverageShsOut 258M 258M 258M 257M 257M 257M
weightedAverageShsOutDil 261M 261M 260M 260M 260M 260M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2024-02-15 2023-11-07 2023-08-02 2023-05-02 2023-02-10 2022-10-28
acceptedDate 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 10 372M 11 110M 10 151M 9 290M 10 504M 9 172M
shortTermInvestments 849M 11 928M 11 236M 1 124M 275M 599M
cashAndShortTermInvestments 11 222M 11 928M 11 236M 10 414M 10 779M 9 771M
netReceivables 1 563M 1 539M 1 556M 1 548M 1 442M 1 385M
inventory 739M 689M 604M 535M 461M 388M
otherCurrentAssets 621M 540M 477M 469M 74M 727M
totalCurrentAssets 14 144M 14 696M 13 873M 12 966M 12 681M 12 271M
propertyPlantEquipmentNet 1 453M 1 435M 1 447M 1 448M 1 108M 1 461M
goodwill 1 088M 1 088M 1 088M 1 088M 1 088M 1 075M
intangibleAssets 840M 604M 604M 604M 604M 604M
goodwillAndIntangibleAssets 1 928M 1 692M 1 692M 1 692M 1 692M 1 679M
longTermInvestments 2 596M 1 700M 1 357M 1 082M 0 0
taxAssets 1 812M 1 729M 1 538M 1 360M 1 247M 1 163M
otherNonCurrentAssets 797M 475M 443M 428M 1 423M 133M
totalNonCurrentAssets 8 586M 7 030M 6 476M 6 009M 5 470M 4 435M
otherAssets 0 0 0 0 0 0
totalAssets 22 730M 21 726M 20 349M 18 974M 18 151M 16 706M
accountPayables 365M 376M 363M 323M 304M 127M
shortTermDebt 84M 0 0 0 89M 0
taxPayables 100M 0 0 0 123M 0
deferredRevenue 170M 0 0 0 160M 0
otherCurrentLiabilities 2 929M 3 224M 2 989M 2 703M 1 878M 2 482M
totalCurrentLiabilities 3 547M 3 599M 3 352M 3 026M 2 431M 2 609M
longTermDebt 725M 745M 768M 789M 472M 825M
deferredRevenueNonCurrent -924M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 924M 0 0 0 0 0
otherNonCurrentLiabilities 878M 869M 759M 727M 1 336M 941M
totalNonCurrentLiabilities 1 602M 1 614M 1 527M 1 516M 1 808M 1 068M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 725M 745M 768M 789M 472M 825M
totalLiabilities 5 150M 5 213M 4 879M 4 542M 4 238M 3 677M
preferredStock 0 0 0 0 0 0
commonStock 3M 258M 258M 3M 3M 3M
retainedEarnings 10 142M 9 174M 8 138M 7 223M 6 523M 5 704M
accumulatedOtherComprehensiveIncomeLoss -14M -3M -40M -13M 800 000 98M
othertotalStockholdersEquity 7 450M 7 084M 7 114M 7 220M 7 387M 7 226M
totalStockholdersEquity 17 580M 16 513M 15 470M 14 432M 13 913M 13 030M
totalEquity 17 580M 16 513M 15 470M 14 432M 13 913M 13 030M
totalLiabilitiesAndStockholdersEquity 22 730M 21 726M 20 349M 18 974M 18 151M 16 706M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 22 730M 21 726M 20 349M 18 974M 18 151M 16 706M
totalInvestments 3 446M 13 628M 12 594M 2 206M 275M 599M
totalDebt 808M 745M 768M 789M 561M 825M
netDebt -9 564M -10 366M -9 384M -8 501M -9 943M -8 347M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VRTX VRTX VRTX VRTX VRTX VRTX
reportedCurrency USD USD USD USD USD USD
cik 875 320 875 320 875 320 875 320 875 320 875 320
fillingDate 2024-02-15 2023-11-07 2023-08-02 2023-05-02 2023-02-10 2022-10-28
acceptedDate 2024-02-15 16:12:14 2023-11-07 16:16:57 2023-08-02 16:05:15 2023-05-02 16:07:33 2023-02-10 16:12:03 2022-10-28 16:07:51
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 969M 1 035M 916M 700M 819M 931M
depreciationAndAmortization 59M 42M 41M 39M 38M 37M
deferredIncomeTax -131M -116M -177M -113M 148M -182M
stockBasedCompensation 209M 131M 119M 122M 112M 136M
changeInWorkingCapital -839M 189M 245M 139M -91M 81M
accountsReceivables 15M -6M -3M -91M 10M -120M
inventory -70M -98M -73M -83M -78M -27M
accountsPayables -32M 9M 36M 36M 160M -70M
otherWorkingCapital -753M 283M 286M 137M -183M 297M
otherNonCashItems -32M -13M -11M 13M 52M -46M
netCashProvidedByOperatingActivities 235M 1 268M 1 134M 900M 1 078M 956M
investmentsInPropertyPlantAndEquipment -116M -41M -60M -42M -34M -54M
acquisitionsNet 0 1M 0 25M 48M 0
purchasesOfInvestments -1 020M -408M -579M -1 842M -275M -228M
salesMaturitiesOfInvestments 218M 331M 335M 50M 484M 194M
otherInvestingActivites 31M -1M 0 -25M -48M -296M
netCashUsedForInvestingActivites -887M -118M -304M -1 834M 176M -384M
debtRepayment -12M -11M -11M -11M -10M -50M
commonStockIssued 46M 15M 0 14M 186M 0
commonStockRepurchased -150M -170M -31M -299M -2M -48M
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -5M 17M 60M 1M -134M 37M
netCashUsedProvidedByFinancingActivities -120M -165M 17M -295M 40M -60M
effectOfForexChangesOnCash 27M -23M 10M 12M 41M -38M
netChangeInCash -744M 963M 858M -1 216M 1 335M 473M
cashAtEndOfPeriod 10 372M 11 117M 10 153M 9 296M 10 512M 9 177M
cashAtBeginningOfPeriod 11 117M 10 153M 9 296M 10 512M 9 177M 8 704M
operatingCashFlow 235M 1 268M 1 134M 900M 1 078M 956M
capitalExpenditure -116M -41M -60M -42M -34M -54M
freeCashFlow 119M 1 228M 1 075M 858M 1 045M 901M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-05 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-01 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-05 21:06 ET
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 21:01 ET
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
2024-01-30 11:28 ET
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
2024-01-17 13:00 ET
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
2024-01-16 19:24 ET
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
2024-01-09 17:42 ET
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
2024-01-07 20:00 ET
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
2023-12-18 21:05 ET
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
2023-12-15 13:12 ET
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-12-13 11:30 ET
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
2023-12-12 00:30 ET
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
2023-12-08 17:52 ET
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
2023-12-05 21:01 ET
Vertex Appoints Nancy Thornberry to its Board of Directors
2023-11-24 14:13 ET
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
2023-11-23 14:05 ET
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
2023-11-16 06:45 ET
 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-11-06 21:01 ET
Vertex Reports Third Quarter 2023 Financial Results
2023-11-02 13:02 ET
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
2023-11-02 12:30 ET
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
2023-10-26 12:00 ET
Vertex to Present at Upcoming Investor Conferences
2023-10-10 12:00 ET
Vertex to Announce Third Quarter 2023 Financial Results on November 6
2023-10-05 12:00 ET
Vertex Appoints Michel Lagarde to its Board of Directors
2023-10-03 22:01 ET
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
2023-09-15 12:52 ET
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
2023-09-14 13:15 ET
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
2023-09-12 11:00 ET
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
2023-08-30 20:01 ET
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
2023-08-29 13:00 ET
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
2023-08-03 12:00 ET
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
2023-08-01 20:01 ET
Vertex Reports Second Quarter 2023 Financial Results
2023-07-05 07:00 ET
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old
2023-06-30 12:01 ET
Vertex to Announce Second Quarter 2023 Financial Results on August 1
2023-06-26 11:30 ET
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
2023-06-23 22:55 ET
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
2023-06-09 15:00 ET
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
2023-06-09 07:01 ET
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
2023-06-08 23:23 ET
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-05-30 12:01 ET
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
2023-05-03 21:07 ET
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
2023-05-01 20:01 ET
Vertex Reports First Quarter 2023 Financial Results
2023-04-26 17:37 ET
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
2023-04-25 12:01 ET
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
2023-04-10 12:05 ET
Vertex to Announce First Quarter 2023 Financial Results on May 1
2023-03-16 12:00 ET
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
2023-03-09 13:00 ET
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
2023-02-21 21:05 ET
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
2023-02-07 21:01 ET
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
2023-01-17 13:00 ET
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
2023-01-04 13:00 ET
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
2022-12-12 13:00 ET
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
2022-11-09 13:00 ET
Vertex to Participate in Upcoming Investor Conferences
2022-11-04 12:00 ET
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
2022-11-03 12:00 ET
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
2022-10-27 20:01 ET
Vertex Reports Third Quarter 2022 Financial Results
2022-10-13 20:05 ET
Vertex to Announce Third Quarter 2022 Financial Results on October 27
2022-10-11 12:00 ET
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
2022-09-08 13:00 ET
Vertex Appoints Jonathan Biller as Chief Legal Officer
2022-09-02 17:15 ET
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
2022-08-31 12:13 ET
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
2022-08-04 20:01 ET
Vertex Reports Second Quarter 2022 Financial Results
2022-07-22 12:00 ET
Vertex Advances VX-548 in Acute and Neuropathic Pain
2022-07-18 20:05 ET
Vertex to Announce Second Quarter 2022 Financial Results on August 4
2022-07-11 12:00 ET
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
2022-07-05 12:00 ET
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
2022-06-10 15:00 ET
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
2022-06-08 20:05 ET
 Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
2022-06-08 12:00 ET
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
2022-06-06 14:00 ET
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
2022-05-31 12:00 ET
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
2022-05-23 12:30 ET
Catalyst Biosciences Sells Complement Portfolio for $60 Million
2022-05-18 14:30 ET
Suketu Upadhyay Elected to Vertex Board of Directors
2022-05-17 10:45 ET
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

SEC forms

Show financial reports only

SEC form 10
2024-02-15 00:00 ET
Vertex Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
Vertex Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-05 00:00 ET
Vertex Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-07 16:16 ET
Vertex Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Vertex Pharmaceuticals published news for 2023 q3
SEC form 8
2023-11-06 16:05 ET
Vertex Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-02 16:05 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-01 16:03 ET
Vertex Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Vertex Pharmaceuticals published news for 2023 q2
SEC form 10
2023-05-02 00:00 ET
Vertex Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-01 00:00 ET
Vertex Pharmaceuticals reported for 2023 q1
SEC form 10
2023-02-10 16:12 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-10 00:00 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-07 16:07 ET
Vertex Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Vertex Pharmaceuticals reported for 2022 q4
SEC form 10
2022-10-28 16:07 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 10
2022-10-28 00:00 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-27 16:06 ET
Vertex Pharmaceuticals published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Vertex Pharmaceuticals reported for 2022 q3
SEC form 6
2022-09-21 16:05 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-05 16:06 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-05 00:00 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 16:08 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Vertex Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-11 08:14 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-05 16:08 ET
Vertex Pharmaceuticals published news for 2022 q2
SEC form 6
2022-05-23 08:41 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-18 16:09 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-18 16:01 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-06 16:03 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-05 16:04 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Vertex Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-03 17:41 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:44 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:42 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-12 16:05 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-07 16:05 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-06 16:59 ET
Vertex Pharmaceuticals published news for 2022 q1
SEC form 10
2022-02-09 16:37 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 10
2022-02-09 00:00 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:29 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:27 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:26 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:24 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:21 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:19 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:17 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:14 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:12 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:09 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:06 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-01 16:09 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-26 16:05 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-26 00:00 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-19 16:24 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-19 16:21 ET
Vertex Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-03 16:18 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-02 16:05 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Vertex Pharmaceuticals published news for 2021 q3
SEC form 10
2021-07-30 16:10 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:05 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Vertex Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-24 07:41 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-19 16:02 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-03 17:05 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-30 16:19 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 16:09 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-20 08:03 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-08 16:03 ET
Vertex Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-08 16:05 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-11 16:03 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-05 16:38 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-01 16:05 ET
Vertex Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-20 08:48 ET
Vertex Pharmaceuticals published news for 2020 q3
SEC form 10
2020-10-30 16:13 ET
Vertex Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-29 16:04 ET
Vertex Pharmaceuticals published news for 2020 q3